ARS Pharmaceuticals Inc., a commercial-stage biopharma company focused on protecting patients from severe allergic reactions, announced a major legal victory: the European Patent Office (EPO) has upheld all claims in EP 3678649, a key patent covering its nasal spray epinephrine formulations containing alkyl-glycosides such as Intravail.
The ruling confirms patent protection across 30+ European countries, reinforcing the company’s global intellectual property coverage for neffy® — its proprietary intranasal epinephrine product — through at least 2039.
Earlier this year, ARS Pharma also successfully defended its U.S. patent (No. 10,682,414), which covers methods of treating type-1 hypersensitivity reactions, including anaphylaxis, using an aqueous nasal spray formulation of epinephrine.
Together, these outcomes mark two decisive wins:
“The EPO’s unanimous decision validates the novelty and strength of our European patent. With both our European and U.S. patents upheld, we’re confident in our ability to defend our global patent estate covering intranasal epinephrine.”
These back-to-back victories fortify ARS Pharma’s IP moat as it expands global access to neffy®, a needle-free epinephrine option for patients at risk of anaphylaxis. The sustained patent protection strengthens the company’s commercial position and reduces future litigation risk across major markets.